Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,777.50 | 6.90 | 0.08% |
CAC 40 | 7,684.68 | 80.43 | -1.04% |
DAX 40 | 23,516.23 | 255.22 | -1.07% |
Dow JONES (US) | 42,197.79 | 769.83 | -1.79% |
FTSE 100 | 8,850.63 | 34.29 | -0.39% |
HKSE | 23,883.87 | 8.69 | -0.04% |
NASDAQ | 19,406.83 | 255.66 | -1.30% |
Nikkei 225 | 38,193.39 | 359.14 | 0.95% |
NZX 50 Index | 12,618.98 | 66.11 | 0.53% |
S&P 500 | 5,976.97 | 68.29 | -1.13% |
S&P/ASX 200 | 8,551.80 | 4.40 | 0.05% |
SSE Composite Index | 3,379.96 | 2.96 | 0.09% |